Theratechnologies Inc. Forecasted to Earn FY2024 Earnings of $0.04 Per Share (NASDAQ:THTX)

Theratechnologies Inc. (NASDAQ:THTX) – Stock analysts at Cantor Fitzgerald boosted their FY2024 earnings per share (EPS) estimates for shares of Theratechnologies in a note issued to investors on Friday, October 11th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will post earnings per share of $0.04 for the year, up from their prior estimate of $0.02. The consensus estimate for Theratechnologies’ current full-year earnings is ($0.02) per share.

Theratechnologies Stock Down 0.7 %

Theratechnologies stock opened at $1.25 on Monday. Theratechnologies has a 52 week low of $0.88 and a 52 week high of $2.58. The company’s 50 day moving average price is $1.27 and its two-hundred day moving average price is $1.33. The stock has a market cap of $57.31 million, a P/E ratio of -6.56 and a beta of 1.41.

Theratechnologies (NASDAQ:THTX) last announced its quarterly earnings results on Thursday, October 10th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.03. The business had revenue of $22.60 million during the quarter. During the same quarter last year, the firm posted ($0.03) earnings per share.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.